%PDF-1.4
%
84 0 obj
<>
endobj
81 0 obj
<>
endobj
134 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-07-09T09:59:18Z
2024-03-28T04:43:19-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T04:43:19-07:00
application/pdf
Heather
2003-251.aug
uuid:faaa4a97-1dd1-11b2-0a00-5609275d6100
uuid:faaa4a99-1dd1-11b2-0a00-aa0000000000
endstream
endobj
70 0 obj
<>
endobj
71 0 obj
<>
endobj
85 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 56 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 58 0 R/Type/Page>>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 60 0 R/Type/Page>>
endobj
40 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 62 0 R/Type/Page>>
endobj
43 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 64 0 R/Type/Page>>
endobj
156 0 obj
[160 0 R]
endobj
157 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Baumgartner)110.7 (, et al: Etaner)36.8 (cept in RA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1537)Tj
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw -58.45 84.8494 Td
(methotrexate. N Engl J Med 1999;340:253-9.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Pincus )17.7 (T)74 (, Callahan LF)79.7 (. )17.7 (T)69.9 (aking mortality in rheumatoid arthritis )]TJ
2.175 -1.25 Td
(seriously \321 predictive markers, socioeconomic status and )Tj
0 -1.25 TD
[(comorbidity)64.8 (. J Rheumatol 1986;13:841-5.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Y)99.8 (oung )54.8 (A, van der Heijde DM. Can we predict aggressive disease?)]TJ
2.175 -1.25 Td
[(Baillieres Clin Rheumatol 1997;1)36.8 (1:27-48.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Y)99.8 (oung )54.8 (A, Dixey J, Cox N, et al. How does functional disability in)]TJ
2.175 -1.25 Td
[(early rheumatoid arthritis \(RA\) af)17.7 (fect patients and their lives?)]TJ
T*
(Results of 5 years of follow-up in 732 patients from the Early RA)Tj
T*
[(Study \(ERAS\). Rheumatology Oxford 2000;39:603-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (elsing PM, van Gestel )54.8 (AM, Swinkels HL, Kiemeney LA, van)]TJ
2.175 -1.25 Td
[(Riel PL. )17.7 (The relationship between disease activity)64.9 (, joint )]TJ
T*
(destruction, and functional capacity over the course of rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 2001;44:2009-17.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Scott DL, Pugner K, Kaarela K, et al. )17.7 (The links between joint)]TJ
2.175 -1.25 Td
(damage and disability in rheumatoid arthritis. Rheumatology)Tj
T*
(Oxford 2000;39:122-32.)Tj
30.825 20 Td
[(19.)-875.1 (Bresnihan B, )54.8 (Alvaro-Gracia JM, Cobby M, et al. )17.7 (T)35 (reatment of)]TJ
2.175 -1.25 Td
(rheumatoid arthritis with recombinant human interleukin-1 receptor)Tj
T*
[(antagonist. )54.8 (Arthritis Rheum 1998;41:2196-204.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Lipsky PE, )17.7 (V)110.8 (an der Heijde DMFM, St Clair EW)91.7 (, et al. Infliximab)]TJ
2.175 -1.25 Td
(and methotrexate in the treatment of rheumatoid arthritis. N Engl )Tj
0 Tc T*
(J Med 2000;343:1594-602.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Strand )17.7 (V)128.9 (.)-0.1 ( )17.7 (T)35 (reatment of active rheumatoid arthritis with leflunomide)]TJ
2.175 -1.25 Td
[(compared with placebo and methotrexate. )54.8 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(1999;159:2542-50.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Emery PBF)79.7 (, Breedfeld FC, Lemmel EM, et al. )54.8 (A)-220.1 (comparison of the)]TJ
2.175 -1.25 Td
[(ef)17.7 (ficacy and safety of leflunomide and methotrexate for the )]TJ
T*
(treatment of rheumatoid arthritis. Rheumatology Oxford)Tj
0 Tc 0 Tw T*
(2000;39:655-65.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Ory P)91.7 (A. Interpreting radiographic data in rheumatoid arthritis. )54.8 (Ann)]TJ
0 Tc 2.175 -1.25 Td
(Rheum Dis 2003;62:597-604.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Lovinger SP)110.7 (. Use of biologics for rheumatoid arthritis tempered by)]TJ
2.175 -1.25 Td
[(concerns over safety)64.8 (, cost. JAMA)-220.2 (2003;289:3229-30.)]TJ
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
64 0 obj
<>stream
8;Z\tCD+K<#_]bg"hBY1Gq;Ns9qCF%c@07D)\0!K1)q%QQ!'MbM0tE7YQt=m%Q9BrY0Kq2j1:`]ZY_
%SCl!G;Z*bQYh=,d7EQ-Z/lQDKql2RI\eLIML(3U)X1d>5b6=c"*I`/RanqYc]L%)
#ksG.8$^R48Sn>Nr$6K71_?T?G=j*'EQA0mR'!9CECi/k,'JCKosh`Us/H=7hFZO/
;I!5LLg2@=-3kb*EjJ?I1a>lC?(Jg2]"_cZJ">Z^'0umIKFgHU+bUCnIM'-:,=+L]
I&ad
endstream
endobj
68 0 obj
[/Indexed/DeviceRGB 255 67 0 R]
endobj
67 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
121 0 obj
<>
endobj
87 0 obj
<>
endobj
91 0 obj
<>
endobj
108 0 obj
<>
endobj
139 0 obj
<>
endobj
90 0 obj
<>
endobj
99 0 obj
<>stream
H|T PYITݚ;Ql9vGL٭oIũu5MVSΓ=:yJ~<\'Wbhel\G>\KԪJu|M